Literature DB >> 18161919

Effect of arsenic trioxide on vascular endothelial cell proliferation and expression of vascular endothelial growth factor receptors Flt-1 and KDR in gastric cancer in nude mice.

Yan-Feng Xiao1, De-Dong Wu, Shan-Xi Liu, Xi Chen, Li-Fen Ren.   

Abstract

AIM: To investigate the effect of arsenic trioxide (As2O3) on expression of vascular endothelial growth factor receptor-1 (VEGFR-1, Flt-1) and VEGFR-2 (KDR) in human gastric tumor cells and proliferation of vascular endothelial cells.
METHODS: The solid tumor model was formed in nude mice with the gastric cancer cell line SGC-7901. The animals were treated with As2O3. Microvessel density (MVD) and expression of Flt-1 and KDR were detected by immunofluorescence laser confocal microscopy. SGC-7901 cells were treated respectively by exogenous recombinant human VEGF165 or VEGF165 + As2O3. Cell viability was measured by MTT assay. Cell viability of ECV304 cells was measured by MTT assay, and cell cycle and apoptosis were analyzed using flow cytometry.
RESULTS: The tumor growth inhibition was 30.33% and 50.85%, respectively, in mice treated with As2O3 2.5 and 5 mg/kg. MVD was significantly lower in arsenic-treated mice than in the control group. The fluorescence intensity levels of Flt-1 and KDR were significantly less in the arsenic-treated mice than in the control group. VEGF165 may accelerate growth of SGC7901 cells, but As2O3 may disturb the stimulating effect of VEGF165. ECV304 cell growth was suppressed by 76.51%, 71.09% and 61.49% after 48 h treatment with As2O3 at 0.5, 2.5 and 5 micromol/L, respectively. Early apoptosis in the As2O3-treated mice was 2.88-5.1 times higher than that in the controls, and late apoptosis was 1.17-1.67 times higher than that in the controls.
CONCLUSION: Our results showed that As2O3 delays tumor growth, inhibits MVD, down-regulates Flt-1 and KDR expression, and disturbs the stimulating effect of VEGF165 on the growth of SGC7901 cells. These results suggest that As2O3 might delay growth of gastric tumors through inhibiting the paracrine and autocrine pathways of VEGF/VEGFRs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18161919      PMCID: PMC4611288          DOI: 10.3748/wjg.v13.i48.6498

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

Review 1.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

Authors:  A W Griffioen; G Molema
Journal:  Pharmacol Rev       Date:  2000-06       Impact factor: 25.468

2.  Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases.

Authors:  M J Edel; J M Harvey; J M Papadimitriou
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Overexpression of vascular endothelial growth factor is responsible for the hematogenous recurrence of early-stage gastric carcinoma.

Authors:  H Konno; M Baba; T Tanaka; K Kamiya; M Ota; K Oba; A Shoji; T Kaneko; S Nakamura
Journal:  Eur Surg Res       Date:  2000       Impact factor: 1.745

Review 4.  Gene therapy strategies for tumor antiangiogenesis.

Authors:  H L Kong; R G Crystal
Journal:  J Natl Cancer Inst       Date:  1998-02-18       Impact factor: 13.506

5.  Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer.

Authors:  Yan-Feng Xiao; Shan-Xi Liu; De-Dong Wu; Xi Chen; Li-Fen Ren
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

Review 6.  Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.

Authors:  A J Murgo
Journal:  Oncologist       Date:  2001

Review 7.  Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.

Authors:  James L Slack; Samuel Waxman; Guido Tricot; Martin S Tallman; Clara D Bloomfield
Journal:  Oncologist       Date:  2002

Review 8.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

Authors:  Napoleone Ferrara
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

9.  VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

Authors:  Yean K Lee; Nancy D Bone; Ann K Strege; Tait D Shanafelt; Diane F Jelinek; Neil E Kay
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113

10.  Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Authors:  Fortunato Ciardiello; Roberto Bianco; Roberta Caputo; Rosa Caputo; Vincenzo Damiano; Teresa Troiani; Davide Melisi; Ferdinando De Vita; Sabino De Placido; A Raffaele Bianco; Giampaolo Tortora
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

View more
  13 in total

1.  Induction of apoptosis and cell cycle arrest in human HCC MHCC97H cells with Chrysanthemum indicum extract.

Authors:  Zong-Fang Li; Zhi-Dong Wang; Yuan-Yuan Ji; Shu Zhang; Chen Huang; Jun Li; Xian-Ming Xia
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

2.  Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction.

Authors:  Edward D Tran; Frank A DeLano; Geert W Schmid-Schönbein
Journal:  J Vasc Res       Date:  2010-02-06       Impact factor: 1.934

3.  Matrix metalloproteinase activity causes VEGFR-2 cleavage and microvascular rarefaction in rat mesentery.

Authors:  Edward D Tran; Ming Yang; Andrew Chen; Frank A Delano; Walter L Murfee; Geert W Schmid-Schönbein
Journal:  Microcirculation       Date:  2011-04       Impact factor: 2.628

4.  Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation.

Authors:  Meng-Hang Yang; Ke-Jie Chang; Jin-Cheng Zheng; Hai Huang; Guang-Yuan Sun; Xue-Wei Zhao; Bing Li; Qing-Yu Xiu
Journal:  Oncol Lett       Date:  2017-07-04       Impact factor: 2.967

5.  Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production.

Authors:  ShiHai Zhang; Jing Zhou; CuiLing Zhang; HuiWen Wu; Yi Wang; JianMin Bian; Jun Guo; XiangYang Wu
Journal:  Med Oncol       Date:  2011-07-20       Impact factor: 3.064

6.  Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model.

Authors:  Eun-Young Kim; Sang Soo Lee; Ji Hoon Shin; Soo Hyun Kim; Dong-Ho Shin; Seung Yon Baek
Journal:  Clin Exp Med       Date:  2013-03-07       Impact factor: 3.984

7.  Low dosage of arsenic trioxide (As2O3) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis.

Authors:  Dehong Luo; Xiaoyuan Zhang; Renle Du; Wenjuan Gao; Na Luo; Shuangtao Zhao; Yi Li; Rui Chen; Hui Wang; Yonghua Bao; Wancai Yang; Daishun Liu; Wenzhi Shen
Journal:  J Biol Inorg Chem       Date:  2018-07-16       Impact factor: 3.358

8.  Potential role of sodium-proton exchangers in the low concentration arsenic trioxide-increased intracellular pH and cell proliferation.

Authors:  Carmen Aravena; Ana R Beltrán; Marcelo Cornejo; Viviana Torres; Emilce S Díaz; Enrique Guzmán-Gutiérrez; Fabián Pardo; Andrea Leiva; Luis Sobrevia; Marco A Ramírez
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

9.  A study on the preparation and characterization of plasmid DNA and drug-containing magnetic nanoliposomes for the treatment of tumors.

Authors:  Zi-Yu Wang; Li Wang; Jia Zhang; Yun-Tao Li; Dong-Sheng Zhang
Journal:  Int J Nanomedicine       Date:  2011-04-27

10.  Thermochemotherapy effect of nanosized As2O3/Fe3O4 complex on experimental mouse tumors and its influence on the expression of CD44v6, VEGF-C and MMP-9.

Authors:  Yiqun Du; Dongsheng Zhang; Hui Liu; Rensheng Lai
Journal:  BMC Biotechnol       Date:  2009-10-05       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.